The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Estimated overall survival (OS) at 7 years was 89.1% with adjuvant T-DM1 versus 84.4% with adjuvant trastuzumab (Herceptin). Consistent with earlier reports from the study, the 7-year invasive ...

HER2-positive breast cancer previously treated with trastuzumab [Herceptin, Genentech] and a taxane, demonstrated substantial improvements in both progression-free survival and overall survival ...

Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab) in Europe has been launched in the UK by MSD. Developed by Korean biosimilar specialists Samsung Bioepsis, MSD is the ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

In patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer, the combination of the CD47 myeloid checkpoint inhibitor evorpacept (ALX148) with trastuzumab (Herceptin), paclitaxel, ...

While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...

particularly among patients who have received treatment with anthracyclines or Herceptin (trastuzumab), they reported. The retrospective analysis of patients with breast cancer prescribed low-dose ...